ID   HMT-3522 T4-2
AC   CVCL_2501
SY   T4-2; T4; HMT-3522/mt-1; mt-1; HMT-3522/massive tumor-1
DR   BTO; BTO:0006210
DR   ArrayExpress; E-TABM-244
DR   cancercelllines; CVCL_2501
DR   ECACC; 98102212
DR   GEO; GSM1172999
DR   GEO; GSM1219379
DR   GEO; GSM1219380
DR   GEO; GSM1219381
DR   GEO; GSM1219382
DR   GEO; GSM1219383
DR   GEO; GSM1219384
DR   GEO; GSM1219385
DR   GEO; GSM1219386
DR   GEO; GSM1219387
DR   GEO; GSM1219388
DR   GEO; GSM1219389
DR   GEO; GSM1219390
DR   GEO; GSM1219391
DR   GEO; GSM1219392
DR   GEO; GSM1219393
DR   GEO; GSM1219394
DR   GEO; GSM1219395
DR   GEO; GSM1219396
DR   GEO; GSM1219397
DR   LINCS_HMS; 51123
DR   PharmacoDB; T4_1558_2019
DR   Wikidata; Q54889970
RX   PubMed=8616848;
RX   PubMed=18316601;
RX   PubMed=18516279;
RX   PubMed=24176112;
CC   Part of: JWGray breast cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 32.94 hours (JWGray panel).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Donor information: Established from a nontumorigenic fibrocystic breast lesion (from parent cell line).
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008359.
CC   Cell type: Epithelial cell of mammary gland; CL=CL_0002327.
ST   Source(s): ECACC=98102212
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,13
ST   D5S818: 9,11
ST   D7S820: 8,9
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 14,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2500 ! HMT-3522 S2
SX   Female
AG   50Y
CA   Spontaneously immortalized cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 19
RX   PubMed=8616848;
RA   Briand P., Nielsen K.V., Madsen M.W., Petersen O.W.;
RT   "Trisomy 7p and malignant transformation of human breast epithelial
RT   cells following epidermal growth factor withdrawal.";
RL   Cancer Res. 56:2039-2044(1996).
RX   PubMed=18316601; DOI=10.1158/0008-5472.CAN-07-2225;
RA   Rizki A., Weaver V.M., Lee S.-Y., Rozenberg G.I., Chin K., Myers C.A.,
RA   Bascom J.L., Mott J.D., Semeiks J.R., Grate L.R., Mian I.S.,
RA   Borowsky A.D., Jensen R.A., Idowu M.O., Chen F.-Q., Chen D.J.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "A human breast cell model of preinvasive to invasive transition.";
RL   Cancer Res. 68:1378-1387(2008).
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).